about
[A case of lung and pleural metastases from breast cancer responding to toremifene]Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling indexRandomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamideSafety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancerAnalysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer.Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistanceCurrent trends of sentinel lymph node biopsy for breast cancer--a surgeon's perspective.HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patientsNeoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?Impact of immediate breast reconstruction on postoperative adjuvant chemotherapy: a single center study.MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.The effects of illness beliefs and chemotherapy impact on quality of life in Japanese and Dutch patients with breast or lung cancer.Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204.The role of interleukin-6 in inhibition of lung metastasis in subcutaneous tumor-bearing mice.Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer.Relationship between the signal ratios of HER-2/CEP17 and c-MYC/CEP17 and the pathological response of neoadjuvant therapy using docetaxel and trastuzumab in breast cancer.[Tolerability and safety of docetaxel plus cyclophosphamide as adjuvant chemotherapy for axillary lymph node-negative breast cancer--JECBC04 trial].Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group.Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study.Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01).[Efficacy and tolerability of controlled-release oxycodone against nab-paclitaxel-induced musculoskeletal pain in breast cancer patients].Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.Cross-cultural comparison of breast cancer patients' Quality of Life in the Netherlands and Japan.Ipsilateral breast tumor relapse after breast conserving surgery in women with breast cancer.99mTc-phytate is better than 99mTc-human serum albumin as a radioactive tracer for sentinel lymph node biopsy in breast cancer.Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 sBRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: a Japanese phase II study.Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multiceAdded value of the presence of blue nodes or hot nodes in sentinel lymph node biopsy of breast cancer.A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance.Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSGAlterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant c[Usefulness of contact thermography for the evaluation of chemotherapeutic effectiveness in breast cancer]Prognostic significance of scoring system based on histological heterogeneity of invasive ductal carcinoma for node-negative breast cancer patients
P50
Q32169421-605F2918-28D4-4460-B0E8-16597BD3F6A2Q33717341-3C123E91-4113-4E08-9D51-240FABD95D58Q33738990-D67A1130-65AB-461B-BDC8-74E24E039034Q34085163-7443B3E1-2639-435B-9E9E-F52849CF8E33Q35765844-73BE95AC-47F0-4855-9AB7-B4B78147AAF9Q36337372-5804CC73-9A16-40A6-B74B-A526EC90DD57Q36475463-41DAE4DD-8E85-4A0F-B1AD-6DE3200A7C26Q36922483-5A81F66F-862C-43C3-9ECD-C9B3126CACE4Q36994920-4ADCCFF4-0216-4192-91E0-0D7C2F2C43B5Q37075632-928AC02A-0141-4B9B-96E9-A39138DAD212Q37812012-E7F70463-0DAD-43A2-B66F-1AC82FACA7A4Q38113703-6ACE3A4B-D6D6-4885-AE3A-124DD66267F7Q38376037-2AFD2280-535D-477C-9159-B75B8BD3A57AQ38393636-7C87770B-59D8-46F9-9667-2CB39ACEC1D9Q39955532-FABB5A79-A4C9-4E63-B6AF-7B067DB671A0Q40655911-07D07B0A-1FF9-4233-AB14-F9FCAA83685AQ40911497-9F3FAA0B-4825-4E44-9E39-E9E393D41B0FQ42117291-2366AD36-87C9-4FB5-8327-7DD598734C4FQ42743375-E1768082-8D83-4D5A-AF3A-9DF917AE5086Q43189434-7C1411A1-0E84-48A3-AC41-CF70D411A892Q43289851-3605FF18-48EA-4490-BC04-F455290007B2Q43843844-021D2F34-005E-4E8C-9F24-499D1A740833Q44605270-4A02347E-99E1-4D5E-A6AF-DA28C1479DABQ44752070-FA79CFDE-8A69-4E35-A2F2-DEEE9E0CF982Q45073151-0FA0B131-DE69-423B-9485-792E54CEA5F7Q45787581-F2B89E93-FA57-457F-8442-6E997BA75FFCQ45881450-4F18503B-7251-4378-AD4F-AEFF3E5161B3Q45922801-309DD554-4BDF-4F2D-8D4D-96D935DFD821Q46956679-514659AE-81EA-48F1-A993-E35493F8A751Q47763725-C8BCE3CC-4C12-4A86-88AB-124B43EC7DAAQ47892546-B05958D8-0651-40DA-B3F5-9740352E011BQ48309954-AD523DB2-271B-49B1-8569-9A1396D305DFQ49970470-458613A8-5E1A-48B6-A001-911C205EB622Q49992953-1C9B55AD-48A5-4261-A1FF-CF27E810AB66Q50479020-F65AEE0E-27C1-4246-8F61-2A7E3D821B2FQ54526078-44B4A794-223F-42C5-8CF1-9DEFB6B70AD7Q55493436-EEEF6520-BD1F-4982-8EDB-C388D6C8D39EQ59652245-D148EDB0-E082-4AA1-9615-98EBE2FAE44BQ70706422-DAA7E132-3F80-4CA1-A8E4-CAEF0D2C1494Q73492634-FB89AC12-8FDF-41C7-B298-AEAB9F2DCF3C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kenichi Inoue
@ast
Kenichi Inoue
@en
Kenichi Inoue
@es
Kenichi Inoue
@nl
Kenichi Inoue
@sl
type
label
Kenichi Inoue
@ast
Kenichi Inoue
@en
Kenichi Inoue
@es
Kenichi Inoue
@nl
Kenichi Inoue
@sl
prefLabel
Kenichi Inoue
@ast
Kenichi Inoue
@en
Kenichi Inoue
@es
Kenichi Inoue
@nl
Kenichi Inoue
@sl
P106
P21
P31
P496
0000-0003-2686-8732